I.N. CHEREZOVA¹, N.KH. GABITOVA¹, I.V. OSIPOVA²

 ¹Kazan State Medical University, Kazan

²Children’s Republican Clinical Hospital, Kazan

Contact details:

Gabitova N.Kh. — Ph. D. (medicine), Associate Professor of the Department of Hospital Pediatrics

Adress: 140 Orenburgskiy trakt, Kazan, Russian Federation, 420059, tel.: +7 (843) 269-67-69, e-mail: borismk1@rambler.ru

Langerhans cell histiocytosis (LCH) is a pathology rarely encountered in clinical practice. This disease has a multifaceted clinical picture, multiorgan damage, a varied course and presents significant diagnostic difficulties due to the lack of generally accepted international algorithms. In the early stages of the disease, patients turn to pediatricians, traumatologists or dermatologists, which leads to frequent diagnostic errors and inadequate therapy. Doctors of various specialties should pay attention to patients with soft tissue swellings, recurrent otitis and dermatitis in the absence of effect from the therapy and promptly refer them to an oncologist. The article presents an analysis of cases of Langerhans cell histiocytosis in children of the Oncohematology Department of the Children’s Republican Clinical Hospital in Kazan over a ten-year period, indicating the characteristic initial features of the disease for early diagnosis at the outpatient stage.

Key words: children, histiocytosis, Langerhans cells, diagnostic.

REFERENCES

1. Rumyantsev A.G., Maschan A.A., Maschan M.A., Novichkova G.A. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu gistiotsitoza iz kletok Langergansa [Federal clinical recommendations for the diagnosis and treatment of histiocytosis from Langerganes cells]. Moscow, 2015. 17 p.
2. Minkov M. Evolution of the treatment of children with histiocytosis from Langergan cells. Pediatriya im. G.N. Speranskogo, 2021, vol. 100, no. 3, pp. 107–120 (in Russ.).
3. Sharova N.M., Kukalo S.V. Langerganosokletty histiocytosis in children. Klinicheskaya dermatologiya i venerologiya, 2021, vol. 20, no. 5, pp. 21–25 (in Russ.). DOI: 10.17116/klinderma20212005121
4. Morimoto A., Oh Y., Shioda Y., Kudo K., Imamura T. Recent advances in Langerhans cell histiocytosis. Pediatr. Int, 2014, vol. 56 (4), rr. 451–461. DOI: 10.1111/PED.12380
5. Khynku E.F., Monaenkova M.K., Tamrazova O.B., Taganov A.V. et al. Histocytosis from Langerganes cells as a clonal disease of the monocytes / macrophages system. Al’manakh klinicheskoy meditsiny, 2022, vol. 50, no. 7, pp. 428–438 (in Russ.). DOI: 10.18786/2072-0505-2022- 50-057
6. Rodriguez-Galindo C. Clinical features and treatment of Langerhans cell histiocytosis. Acta Paediatr, 2021, vol. 110 (11), pp. 2892–2902. DOI: 10.1111/apa.16014
7. Berres M.L, Lim K.P., Peters T., Price J. et al BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J. Exp. Med, 2014, vol. 211 (4), pp. 669–683. DOI: 10.1084/jem.20130977
8. Latyshev V.D., Lukina E.A. Histiocytosis from Langerganes cells in adults: Modern possibilities of therapy. Klinicheskaya onkogematologiya, 2021, vol. 14, no. 4, pp. 444–454 (in Russ.). DOI: 10.21320/2500-2139-2021-14-4-444-454
9. Feng C., Li Y., Ke H., Peng X., Guo H., Zhan L. et al. Immune microenvironment in Langerhans cell histiocytosis: potential prognostic indicators. Front. Oncol, 2021, vol. 11, rr. 631–682. DOI: 10.3389/fonc.2021.631682
10. Burtsev E.A., Bronin G.O. Histocytosis from Langerganes cells in children: Review of literature. Voprosy sovremennoy pediatrii, 2023, vol. 22, no. 1, pp. 13–22 (in Russ.). DOI: 10.15690/vsp.v22i1.2520
11. Gur’eva O.D., Valiev T.T., Pavlovskaya A.I. Histiocytic tumors: modern aspects of pathogenesis, classification, diagnosis and treatment. Onkogematologiya, 2022, vol. 17, no. 1, pp. 10–25 (in Russ.). DOI: 10.17650/1818-8346-2022-17-1-10-25
12. Hogstad B., Berres ML., Chakraborty R., Tang J., Bigenwald C, Serasinghe M. et al. RAF/MEK/ extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J. Exp. Med, 2018, vol. 215 (1), rr. 319–336.
13. Leung A.K.C., Lam J.M., Leong K.F. Childhood Langerhans cell histiocytosis: a disease with many faces. World J. Pediatr, 2019, vol. 15 (6), rr. 536–545. DOI: 10.1007/s12519-019-00304-9
14. Vaiani E., Felizzia G., Lubieniecki F., Braier J., Belgorosky A. Paediatric Langerhans cell histiocytosis disease: long-term sequelae in the hypothalamic endocrine system. Horm. Res. Paediatr, 2021, vol. 94 (1–2), pp. 9–17. DOI: 10.1159/000517040
15. Belysheva T.S., Valiev T.T., Murashkin N.N. Dermatological masks of histiocytosis from Langerganes cells. Clinical case. Consilium Medicum, 2022, vol. 24, no. 8, pp. 541–546 (in Russ.). DOI: 10.26442/20751753.2022.8.201817
16. McKenzie S., Vecerek N., Kang Y., Knowles B., Hogeling M. A neonatal pustule: Langerhans cell histiocytosis. Dermatol Online. J. Pub. Med, 2019, vol 25 (8), pp. 13030/qt6hr0w31v
17. Morren M.A., van Den Broecke K., Vangeebergen L., Sillevis-Smitt J.H., van Den Berghe P. et al. Diverse cutaneous presentations of Langerhans cell histiocytosis in children: a retrospective cohort study. Pediatr. Blood Cancer, 2016, vol. 63 (3), pp. 486–492. DOI: 10.1002/pbc.25834
18. Yaeger R., Corcoran R.B. Targeting alterations in the RAF-MEK Pathway. Cancer Discov, 2019, vol. 9 (3), pp. 329–341. DOI: https://doi.org/ 10.1158/2159-8290.CD-18-1321
19. Gargano F., Welch J.J, Klinge P.M, Sullivan S.R, Taylor H.O. Langerhans cell histiocytosis in the pediatric population: treatment of isolated craniofacial lesions. J. Craniofac. Surg, 2019, vol. 30 (4), pp. 1191–1193. DOI: 10.1097/SCS.0000000000005249
20. Vologina N.I., Kalenich L.A. The syndrome of the «empty» Turkish saddle. Mezhdunarodnyy zhurnal eksperimental’nogo obrazovaniya, 2015, vol. 5, no. 1, pp. 25–26 (in Russ.).